Testosterone Replacement Therapy Versus Clomiphene Citrate in the Young Hypogonadal Male

Eur Urol Focus. 2018 Apr;4(3):321-323. doi: 10.1016/j.euf.2018.07.033. Epub 2018 Aug 18.

Abstract

The use of testosterone to treat hypogonadal symptoms has increased during the past decade. Consequently, one clinical challenge that has arisen is how to approach the young and treatment-naïve hypogonadal patient who is still within his reproductive years and may desire children in the future. Testosterone is known to suppress the hypothalamic-pituitary-gonadal axis resulting in suppressed spermatogenesis. There is a concern that, in some men, prolonged testosterone use may result in permanent spermatogenic failure. PATIENT SUMMARY: In this review, we discuss the risks and benefits of available treatment options for the young hypogonadal patient for whom future fertility is an important consideration. Fortunately, alternatives such as clomiphene citrate and human chorionic gonadotropin have been shown to increase endogenous testosterone production. However, their efficacy as treatments for hypogonadal symptoms is still under debate.

Keywords: Clomiphene citrate; Fertility; Hypogonadism; Testosterone.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Chorionic Gonadotropin / administration & dosage
  • Chorionic Gonadotropin / therapeutic use
  • Clomiphene / administration & dosage
  • Clomiphene / therapeutic use*
  • Estrogen Antagonists / administration & dosage
  • Estrogen Antagonists / therapeutic use
  • Fertility / drug effects*
  • Fertility / physiology
  • Hormone Replacement Therapy / methods*
  • Humans
  • Hypogonadism / drug therapy*
  • Hypothalamo-Hypophyseal System / drug effects
  • Male
  • Spermatogenesis / drug effects
  • Testosterone / administration & dosage
  • Testosterone / therapeutic use*

Substances

  • Chorionic Gonadotropin
  • Estrogen Antagonists
  • Clomiphene
  • Testosterone